Hematoma

35

Pipeline Programs↗

11

Active Trials↗

19

Companies Involved↗

Hematoma is a moderately active landscape with 35 programs across 19 companies. The most active players are Neurim Pharmaceuticals Ltd., Novo Nordisk, Pfizer's Upjohn has merged with Mylan to form Viatris Inc.. 14 therapies are approved with 3 more in late-stage development.

Intelligence

Pipeline Metrics

Competitive Density

56/100

Pipeline Velocity

22/100

Mech. Concentration

10/100

Completion Rate

62/100

Attrition Rate

20/100

Competition

Competitive Landscape

Bubble size = clinical trials

Approved

Phase 3

Phase 2

Phase 1

Preclinical

Key Players

Top Companies

Neurim Pharmaceuticals Ltd.

1 program

Novo Nordisk

1 program

Pfizer's Upjohn has merged with Mylan to form Viatris Inc.

1 program

Boehringer Ingelheim

1 program

Pfizer

1 program

Novartis

1 program

Pipeline

Programs by Phase

Preclinical11

Epinephrine

Samson Clinical Operations Pty Ltd

Low-Molecular-Weight Heparin

Daiichi Sankyo

Acetylsalicylic Acid

Bayer

Perindopril

Institut de Recherches Internationales Servier

Aspirin Continuation

Tao Liu

Phase 13

Melatonin

Neurim Pharmaceuticals Ltd.

Memantine Hydrochloride

Forest Laboratories

Curcumin Pill

Shahid Beheshti University of Medical Sciences

Phase 24

Bevacizumab

Bio-Thera Solutions

Atorvastatin

Pfizer's Upjohn has merged with Mylan to form Viatris Inc.

Atorvastatin and Dexamethasone

Oriental Neurosurgery Evidence-Based-Study Team

Humscs

Second Affiliated Hospital, School of Medicine, Zhejiang University

Phase 33

Dabigatran

Boehringer Ingelheim

Methylprednisolone

Pfizer

Dexamethasone

Aspen Global Incorporated

Approved14

Tranexamic Acid

Amring

Propofol

Fresenius Kabi Oncology Ltd.

Bupivacaine

Innocoll

Apixaban

Bristol-Myers Squibb

Lidocaine

MEDRx USA, Inc.

Analysis

Modality Breakdown

98%

Small molecule

40 of 41 classified programs — the dominant modality here.

Small molecule leads; the ring shows all 41 classified programs, each share of the total. Modality classified for 100% of 43 pipeline programs.

Analysis

Trial Status

51

clinical trials

Completed16 · 31%

Unknown status14 · 27%

Terminated7 · 14%

Recruiting6 · 12%

Not yet recruiting4 · 8%

Withdrawn3 · 6%

Other1 · 2%

Clinical Trials

Trial Activity

51 trials

Aspirin Continuation or Discontinuation in Conservative Treatment for Chronic Subdural Hematoma

Recruiting·—·N/A·NCT07240454·143 enrolled

Scalp Block Versus General Anesthesia in Patients Undergoing Evacuation of Subdural Hematoma Via Burr Hole

Recruiting·SSohag University·N/A·NCT07143799·80 enrolled

Tranexamic Acid to Prevent OpeRation in Chronic Subdural Hematoma

Recruiting·—·Phase 3·NCT03582293·554 enrolled

Acute EpiDural Hematoma Treated With Middle Meningeal Artery Embolization: a Randomized Trial (AEDH-MT)

Recruiting·—·N/A·NCT06292585·194 enrolled

Chronic Subdural Hematoma Treatment With Intra-Arterial Bevacizumab Injection

Recruiting·TThe Cooper Health System·Phase 1/2·NCT06510582·140 enrolled

Adjuvant Tranexamic Acid (TXA) Versus Surgery Alone for Adult Patients With Chronic Subdural Hematoma (CSDH)

Recruiting·SSt. Olavs Hospital·Phase 2/3·NCT07245264·274 enrolled

Hematoma Block Versus Bier Block for Closed Fracture Reduction

Active, not recruiting·UUniversity of Utah·Phase 1·NCT05086224·500 enrolled

Platelet Activity Monitoring for Patients Under Adp Medication Using Verify Now in Subdural Hematoma

Not yet recruiting·UUniversity Hospital, Brest·N/A·NCT06415422·40 enrolled

The Use of Tranexamic Acid in the Treatment of Symptomatic Subdural Hematoma

Not yet recruiting·UUnity Health Toronto·Phase 3·NCT05713630·130 enrolled

Tranexamic Acid Therapy For The Treatment of Subdural Hematomas

Not yet recruiting·—·Phase 2·NCT06718751·240 enrolled

Efficacy and Safety of Chinese Herbal HuoXue LiShui Formula for Chronic Subdural Hematoma

Not yet recruiting·—·N/A·NCT06427980·160 enrolled

Efficacy of Hematoma Block on Postoperative Pain After Femoral Intramedullary Rodding: A Randomized Trial

Completed·UUniversity of Cincinnati·Phase 4·NCT04860856·88 enrolled

Utility of Real-Time Contrast Enhanced Ultrasound (CEUS) in the Evaluation of Soft Tissue Hematomas

Completed·MMayo Clinic·N/A·NCT03357081·16 enrolled

Influence of Acetylsalicylic Acid and Low Molecular Weight Heparins on the Incidence of Renal Hematoma of Shockwave Lithotripsy

Completed·KKantonsspital Winterthur KSW·N/A·NCT02875717·500 enrolled

Treatment of Chronic Subdural Hematoma by Corticosteroids

Completed·RRennes University Hospital·Phase 3·NCT02650609·202 enrolled

Page 1 of 4

Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)